[go: up one dir, main page]

AR119943A1 - Compuestos heterocíclicos - Google Patents

Compuestos heterocíclicos

Info

Publication number
AR119943A1
AR119943A1 ARP200102527A ARP200102527A AR119943A1 AR 119943 A1 AR119943 A1 AR 119943A1 AR P200102527 A ARP200102527 A AR P200102527A AR P200102527 A ARP200102527 A AR P200102527A AR 119943 A1 AR119943 A1 AR 119943A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
alkoxy
compounds
cycloalkyl
Prior art date
Application number
ARP200102527A
Other languages
English (en)
Inventor
Bernd Puellmann
Fionn Ohara
Rainer E Martin
Bernd Kuhn
Carsten Kroll
Benoit Hornsperger
Zbinden Katrin Groebke
Uwe Grether
Luca Gobbi
Joerg Benz
Martin Ritter
Hans Richter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67953598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR119943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119943A1 publication Critical patent/AR119943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente proporciona compuestos heterocíclicos que tienen la fórmula general (1) en donde A, B, L¹, X, m, n, y R¹ a R⁷ son como se describen en la presente, composiciones que incluyen los compuestos, procesos de elaboración de los compuestos y métodos de uso de los compuestos. Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A se selecciona de C₆₋₁₄-arilo, heteroarilo de 5 a 14 miembros y heterociclilo de 3 a 14 miembros; B es (i) C₆₋₁₄-arilo; y L¹ es -O-; o (ii) heteroarilo de 5 a 14 miembros; y L¹ es un enlace covalente u -O-; m es 0, n es 0 ó 1 y X es CR⁸; o m es 1, n es 1 ó 2 y X es CR⁸ o N; R¹, R² y R³ se seleccionan independientemente de hidrógeno y C₁₋₆-alquilo; R⁴, R⁵, R⁶ y R⁷ se seleccionan independientemente de hidrógeno, halógeno, ciano, hidroxi, C₁₋₆-alcoxi, halo-C₁₋₆-alcoxi, amino-C₁₋₆-alcoxi, C₁₋₆-alquilo, halo-C₁₋₆-alquilo, hidroxi-C₁₋₆-alquilo, C₁₋₆-alquilsulfonilo, SF₅, carbamoilo, C₃₋₁₀-cicloalquil-C₁₋₆-alcoxi-, C₁₋₆-alquil-NH-C(O)-, C₁₋₆-alquil-C(O)-NH- y C₃₋₁₀-cicloalquilo, en donde cada uno de C₃₋₁₀-cicloalquilo está opcionalmente sustituido con 1 - 2 sustituyentes seleccionados de C₁₋₆-alquilo y halo-C₁₋₆-alquilo; y R⁸ se selecciona de hidrógeno, halógeno, hidroxi, halo-C₁₋₆-alquilo y C₁₋₆-alquilo.
ARP200102527A 2019-09-12 2020-09-11 Compuestos heterocíclicos AR119943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19196879 2019-09-12

Publications (1)

Publication Number Publication Date
AR119943A1 true AR119943A1 (es) 2022-01-19

Family

ID=67953598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102527A AR119943A1 (es) 2019-09-12 2020-09-11 Compuestos heterocíclicos

Country Status (18)

Country Link
US (1) US11814375B2 (es)
EP (1) EP4028403B1 (es)
JP (1) JP7609854B2 (es)
KR (1) KR20220062515A (es)
CN (1) CN114269755A (es)
AR (1) AR119943A1 (es)
AU (1) AU2020346350A1 (es)
BR (1) BR112022002375A2 (es)
CA (1) CA3151516A1 (es)
CL (1) CL2022000556A1 (es)
CO (1) CO2022001879A2 (es)
CR (1) CR20220104A (es)
IL (1) IL289186A (es)
MX (1) MX2022002311A (es)
PE (1) PE20220565A1 (es)
PH (1) PH12022550339A1 (es)
TW (1) TW202128706A (es)
WO (1) WO2021048242A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
JP7637049B2 (ja) 2018-08-13 2025-02-27 エフ． ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
JP2022543106A (ja) 2019-07-30 2022-10-07 エイコニゾ セラピューティクス，インコーポレーテッド Ｈｄａｃ６インヒビターおよびそれらの使用
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds
MX2023012875A (es) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN116410483A (zh) * 2023-04-14 2023-07-11 沈阳工业大学 一种羰基联氮杂环超分子鎓盐及其制备方法与应用
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
US7408066B2 (en) 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
MX2008010481A (es) 2006-02-17 2008-12-19 Memory Pharm Corp Compuestos que tienen afinado para el receptor f-ht6.
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
FR2915199B1 (fr) * 2007-04-18 2010-01-22 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
CN102203065B (zh) 2008-10-29 2014-07-09 霍夫曼-拉罗奇有限公司 新的苯基酰胺或吡啶基酰胺衍生物和它们作为gpbar1激动剂的应用
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP2013540160A (ja) * 2010-10-22 2013-10-31 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのアミノ−ピロリジン−アゼチジンジアミド
AU2012255690B2 (en) 2011-05-16 2015-06-11 Bionomics Limited Amine derivatives as potassium channel blockers
US20140288323A1 (en) 2011-10-19 2014-09-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
US9029368B2 (en) 2011-11-30 2015-05-12 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics
PT2794600T (pt) 2011-12-22 2018-03-13 Novartis Ag Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
SG11201508479RA (en) 2013-04-16 2015-11-27 Actelion Pharmaceuticals Ltd Antibacterial biaromatic derivatives
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
WO2016158956A1 (ja) * 2015-03-30 2016-10-06 武田薬品工業株式会社 複素環化合物
US20180148429A1 (en) 2015-05-13 2018-05-31 Selvita S.A. Substituted quinoxaline derivatives
ES2945314T3 (es) 2015-05-21 2023-06-30 Glaxosmithkline Ip Dev Ltd Derivados de benzoimidazol como inhibidores de PAD4
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
US10385057B2 (en) * 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EA039223B1 (ru) 2017-06-12 2021-12-20 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
EP3689879B1 (en) 2017-09-29 2025-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
RS64156B1 (sr) * 2018-03-22 2023-05-31 Hoffmann La Roche Oksazinski inhibitori monoacilglicerol lipaze (magl)
JP7637049B2 (ja) 2018-08-13 2025-02-27 エフ． ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
AU2019322161A1 (en) * 2018-08-13 2020-11-12 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
CN113227068B (zh) 2018-11-22 2023-06-13 上海齐鲁锐格医药研发有限公司 Glp-1r激动剂及其用途
MA55131B1 (fr) 2018-11-22 2023-10-31 Hoffmann La Roche Nouveaux composés hétérocycliques
JP7707073B2 (ja) 2019-04-09 2025-07-14 エフ． ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
MX2022000083A (es) 2019-07-03 2022-02-03 Hoffmann La Roche Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.
AU2020311584A1 (en) 2019-07-09 2022-01-20 F. Hoffmann-La Roche Ag New heterocyclic compounds
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
CN114650994A (zh) 2019-09-12 2022-06-21 豪夫迈·罗氏有限公司 放射性标记的化合物
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
JP2022549810A (ja) 2019-09-23 2022-11-29 エフ．ホフマン－ラ ロシュ アーゲー 複素環化合物
CN114401968A (zh) 2019-09-24 2022-04-26 豪夫迈·罗氏有限公司 新颖杂环单酰基甘油脂肪酶(magl)抑制剂
EP4034541A1 (en) * 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Heterocyclic compounds
EP4034602A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Fluorescent probes for monoacylglycerol lipase (magl)
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds

Also Published As

Publication number Publication date
CL2022000556A1 (es) 2022-10-21
CR20220104A (es) 2022-04-20
BR112022002375A2 (pt) 2022-07-19
JP2022548028A (ja) 2022-11-16
US20210094943A1 (en) 2021-04-01
US11814375B2 (en) 2023-11-14
JP7609854B2 (ja) 2025-01-07
WO2021048242A1 (en) 2021-03-18
CO2022001879A2 (es) 2022-03-29
IL289186A (en) 2022-02-01
TW202128706A (zh) 2021-08-01
MX2022002311A (es) 2022-03-25
EP4028403C0 (en) 2023-11-22
PH12022550339A1 (en) 2023-03-13
CN114269755A (zh) 2022-04-01
EP4028403A1 (en) 2022-07-20
AU2020346350A1 (en) 2022-02-17
KR20220062515A (ko) 2022-05-17
EP4028403B1 (en) 2023-11-22
CA3151516A1 (en) 2021-03-18
PE20220565A1 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
AR119943A1 (es) Compuestos heterocíclicos
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR120697A1 (es) Inhibidores de braf como rompedores de la paradoja
AR116666A1 (es) Compuestos heterocíclicos
AR120030A1 (es) Compuestos heterocíclicos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
PE20221336A1 (es) Compuestos triciclicos sustituidos
AR111279A1 (es) Derivados heterocíclicos útiles como inhibidores duales de atx / ca
MX2025009239A (es) Compuestos triciclicos para el tratamiento de cancer
AR113929A1 (es) Compuestos heterocíclicos
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR122517A1 (es) Isoxazolidinas como inhibidores de ripk1 y usos de las mismas
AR121985A1 (es) Compuestos de azalactama como inhibidores de hpk1
AR120029A1 (es) Compuestos heterocíclicos
AR122726A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
AR129299A1 (es) Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
AR119790A1 (es) Compuestos de isoxazolina y su uso como agentes para el control de plagas
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
AR119376A1 (es) Compuestos heterocíclicos
AR116905A1 (es) Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor
AR116906A1 (es) Derivados de heteroarilo bicíclico
AR123121A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal